Patents by Inventor Alex Blyth
Alex Blyth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260258362Abstract: A method of preparing cells for therapeutic use is provided, in which a population of progenitor cells is cultured in cell culture conditions that promote differentiation of the progenitor cells comprising the presence of: G-CSF, GM-CSF, IL-3 and TNF; to produce a population of granulopoietic cells. The granulopoietic cells produced may be useful in methods of treatment, including the treatment of cancer and infections, and to modulate inflammatory cell responses.Type: ApplicationFiled: March 8, 2024Publication date: September 3, 2026Applicant: LIFT BioSciences LtdInventors: Alex Blyth, Oxana POLYAKOVA, Aoife MCGINLEY, Samuel FLORENCE, Mihil PATEL, Durva PATEL, Andrew WILLIS
-
Publication number: 20260207663Abstract: The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.Type: ApplicationFiled: July 2, 2025Publication date: July 23, 2026Applicant: LIfT BioSciences LtdInventors: Alex Blyth, Nico Bruyniks
-
Publication number: 20250325584Abstract: The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.Type: ApplicationFiled: July 2, 2025Publication date: October 23, 2025Applicant: LIfT BioSciences LtdInventors: Alex Blyth, Nico Bruyniks
-
Patent number: 12370216Abstract: The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.Type: GrantFiled: March 24, 2023Date of Patent: July 29, 2025Assignee: LIft BioSciences LtdInventors: Alex Blyth, Nico Bruyniks
-
Publication number: 20240285681Abstract: The invention relates to a granulocyte or stem cell (preferably granulocyte) for use in treating an infection. The invention also relates to said methods for identifying said granulocytes and stem cells capable of differentiating into said granulocytes, compositions and kits comprising the same, as well as uses of the same for treating an infection.Type: ApplicationFiled: December 11, 2020Publication date: August 29, 2024Inventor: Alex Blyth
-
Patent number: 12070473Abstract: The present invention relates to an in vitro culture of haematopoietic cells, wherein the haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to the granulocytes, methods for identifying the haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.Type: GrantFiled: April 24, 2018Date of Patent: August 27, 2024Assignee: LIFT BIOSCIENCES LTDInventors: Alex Blyth, Nico Bruyniks
-
Publication number: 20240197776Abstract: The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.Type: ApplicationFiled: November 17, 2023Publication date: June 20, 2024Inventors: Alex Blyth, Nico Bruyniks
-
Patent number: 11878033Abstract: The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.Type: GrantFiled: April 24, 2018Date of Patent: January 23, 2024Assignee: LIFT BIOSCIENCES LTDInventors: Alex Blyth, Nico Bruyniks
-
Publication number: 20230346834Abstract: The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.Type: ApplicationFiled: March 24, 2023Publication date: November 2, 2023Applicant: LIfT BioSciences LtdInventors: Alex Blyth, Nico Bruyniks
-
Publication number: 20230203441Abstract: The invention relates to a method for determining the suitability of a granulocyte for treating cancer. The invention also relates to said granulocytes, methods for identifying said granulocytes and stem cells capable of differentiating into said granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.Type: ApplicationFiled: December 11, 2020Publication date: June 29, 2023Inventor: Alex Blyth
-
Patent number: 11642373Abstract: The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.Type: GrantFiled: October 25, 2017Date of Patent: May 9, 2023Assignee: LIfT Biosciences LtdInventors: Alex Blyth, Nico Bruyniks
-
Publication number: 20210189340Abstract: The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.Type: ApplicationFiled: April 24, 2018Publication date: June 24, 2021Inventors: Alex Blyth, Nico Bruyniks
-
Publication number: 20190314409Abstract: The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.Type: ApplicationFiled: October 25, 2017Publication date: October 17, 2019Inventors: Alex Blyth, Nico Bruyniks
